Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598962 · ClinicalTrials.gov registry record · Phase 4
Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease
A Phase 4 study, sponsored by The University of Texas Health Science Center at Tyler.
- Completed
- Registry status
- Phase 4
- Development phase
- 58
- Enrollment target
NCT00598962: Completed Phase 4 study, sponsored by The University of Texas Health Science Center at Tyler.
NCT00598962 is a Phase 4 study that has completed, run by The University of Texas Health Science Center at Tyler. The registered enrollment target is 58 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00598962, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center at Tyler.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 58 participants
- Enrollment target
Study Summary
To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)
Interventions
- DRUG Azithromycin
- DRUG Rifabutin/rifampin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 1994-12 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598962
The ClinicalTrials.gov registry entry for NCT00598962 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (89% lower). The listed sponsor is The University of Texas Health Science Center at Tyler, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azithromycin is the first listed.
NCT00598962 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598962 about?
NCT00598962 is a clinical study titled "Use of Azithromycin and Rifabutin Administered 3 Times Weekly for the Treatment of M. Avium Complex (MAC) Lung Disease". To determine the safety and efficacy of azithromycin, rifabutin and ethambutol given three times weekly in the treatment of lung infection with M. avium complex(MAC)
What is the current status of trial NCT00598962?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 58 participants. The study started on 1994-12. Estimated completion is 2017-05-18.
What interventions are being tested in trial NCT00598962?
The interventions under investigation include: Azithromycin (DRUG), Rifabutin/rifampin (DRUG).
Who is sponsoring clinical trial NCT00598962?
This trial is sponsored by The University of Texas Health Science Center at Tyler, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.